CORRELATION BETWEEN LYMPHOCYTE AND CLINICAL SEVERITY OF COVID-19 IN BANDA ACEH, INDONESIA
Keywords:Lymphocyte, COVID-19, lung lesion severity, clinical severity, outcome
The coronavirus disease 2019 (COVID-19) pandemic has caused a global health crisis and is a source of increased morbidity and mortality in the world. COVID-19 caused by SARS-CoV-2 affects the proliferation of lymphocytes, but the clinical significance of lymphocytes remains unclear. Therefore, this study aims to analyze the relationship between lymphocytes with the clinical severity of COVID-19. The retrospective study design collected medical records of demographic data, chest X-rays, and laboratory tests at the time of hospital admission for confirmed patients. Furthermore, the severity of the disease was divided into moderate, severe, and very severe degrees. The severity of lung injury was assessed based on the Brixia Score, and the clinical outcome of patients had criteria of recovered and died. This study has collected 100 COVID-19 patients above 60 years (39%) with male gender (66%). The Majority of patients with low lymphocyte levels (51%), severe lung injury (45%), and one-third of the treated cases ended in death (33.0%), and most of them recovered (67%). Furthermore, low lymphocyte levels were associated with severe and critically ill severity and death (p<0.05). Almost all lung damage was detected in severe and critically ill severity, and Brixia scores were detected high in patients with low lymphocyte levels (51.0%)(p>0.05). lymphocyte can be an indicator of clinical severity and mortality for COVID-19 patients. This study shows that lymphocyte count may help identify patients with severe diseases. Therefore, observation of the lymphocyte count is necessary for the initial screening, diagnosis, and treatment of COVID-19 patients.
Yanti B, Maulana I, Sofiana D, Sufani L, Jannah N. Nasal rinse and gargling as an effort in preventing COVID-19 infection with Islamic approach- a literature review. 2021;10(2):503–6.
Li H, Liu S, Yu X, Tang S, Tang C. Coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Int J Antimicrob Agents 2020;55(5):105951.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol [Internet] 2021;19(3):141–54. Available from: http://dx.doi.org/10.1038/s41579-020-00459-7
Sohrabi C, Alsafi Z, Neill NO, Khan M, Kerwan A. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).
Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun 2020;11(1):1–9.
Ruocco G, Feola M, Palazzuoli A. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. Int J Infect Dis 2020;95:373–5.
Efrina D, Priyanto H, Andayani N, Arliny Y, Yanti B. Neutrophil To Lymphocyte Ratio as A Marker of Covid-19 Disease Severity in Banda Aceh, Indonesia. J Respirologi Indones 2021;41(4):1–7.
Wagner J, DuPont A, Larson S, Cash B, Farooq A. Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. Int J Lab Hematol 2020;42(6):761–5.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet] 2020;395(10223):507–13. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30211-7
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J Intensive Care 2020;8(1):1–10.
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in covid-19 pneumonia. J Infect Dis 2020;221(11):1762–9.
Cantenys-Molina S, Fernández-Cruz E, Francos P, Lopez Bernaldo de Quirós JC, Muñoz P, Gil-Herrera J. Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain. Clin Exp Immunol 2021;203(3):424–32.
Wang X, Che Q, Ji X, Meng X, Zhang L, Jia R, et al. Correlation between lung infection severity and clinical laboratory indicators in patients with COVID-19: a cross-sectional study based on machine learning. BMC Infect Dis 2021;21(1):1–9.
Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study. Cancers (Basel) 2021;13(3):1–15.
Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis 2020;26(8):1839–41.
Zhao Q, Meng M, Kumar R, Wu Y, Huang J. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis 2020;96(January):131–135.
Taherdoost H. Sampling Methods in Research Methodology ; How to Choose a Sampling Technique for Research Hamed Taherdoost To cite this version : HAL Id : hal-02546796 Sampling Methods in Research Methodology ; How to Choose a Sampling Technique for. Int J Acad Res Manag 2016;5(2):18–27.
Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization; 2020.
Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Medica [Internet] 2020;125(5):509–13. Available from: https://doi.org/10.1007/s11547-020-01200-3
Herbinger KH, Hanus I, Beissner M, Berens-Riha N, Kroidl I, Von Sonnenburg F, et al. Lymphocytosis and lymphopenia induced by imported infectious diseases: A controlled cross-sectional study of 17,229 diseased German travelers returning from the tropics and subtropics. Am J Trop Med Hyg 2016;94(6):1385–91.
Nicholson JKA, Stein D, Mui T, Mack R, Hubbard M, Denny T. Evaluation of a method for counting absolute numbers of cells with a flow cytometer. Clin Diagn Lab Immunol 1997;4(3):309–13.
Giesecke J. The invisible pandemic. Lancet. 2020;395(10238):e98.
Hu C, Li J, Xing X, Gao J, Zhao S, Xing L. The effect of age on the clinical and immune characteristics of critically ill patients with COVID-19: A preliminary report. PLoS One. 2021;16(3 March):1–1
Rui L, Sirui L, Xuebei D, Xujun Y, Yanggan W. Clinical observations in very elderly patients with COVID-19 in Wuhan. Geriatr Gerontol Int. 2020;20(7):709–14.
Peltzer K, Pengpid S. The Prevalence and Social Determinants of Hypertension among Adults in Indonesia: A Cross-Sectional Population-Based National Survey. Int J Hypertens. 2018;2018:5610725
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Pimentel MAF, Redfern OC, Hatch R, Young JD, Tarassenko L, Watkinson PJ. Trajectories of vital signs in patients with COVID-19. Resuscitation. 2020;156(September):99–106.
Ma A, Cheng J, Yang J, Dong M, Liao X, Kang Y. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care. 2020;24(1):24–7.
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8(1).
Bobcakova A, Petriskova J, Vysehradsky R, Kocan I, Kapustova L, Barnova M, et al. Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome. Front Cell Infect Microbiol. 2021;11(April):1–15.
Wang YY, Jin YH, Ren XQ, Li YR, Zhang XC, Zeng XT, et al. Updating the diagnostic criteria of COVID-19 “suspected case” and “confirmed case” is necessary. Mil Med Res. 2020;7(1):10–2.
Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.